Treatment effects of DC101 (anti–murine VEGFR-2) and 6.12 (anti–human VEGFR-1) antibodies on RL lymphoma xenografts
Agent . | Dose . | Average tumor diameter, mm ± SE . | Average tumor volume (TV), mm3 ± SE . | P for TV IVIG vs treatment . |
|---|---|---|---|---|
| IVIG | 800 μg 2×/wk | 14.9 ± 0.3 | 1748 ± 115 | NA |
| DC101 | 400 μg 3×/wk | 11.6 ± 0.4 | 896 ± 95 | ≤ .001 |
| 6.12 | 800 μg 2×/wk | 12.0 ± 0.5 | 941 ± 115 | ≤ .001 |
| 6.12 + DC | 800 μg 2×/wk and 400 μg 3×/wk | 9.9 ± 0.6 | 558 ± 103 | ≤ .0001 |
Agent . | Dose . | Average tumor diameter, mm ± SE . | Average tumor volume (TV), mm3 ± SE . | P for TV IVIG vs treatment . |
|---|---|---|---|---|
| IVIG | 800 μg 2×/wk | 14.9 ± 0.3 | 1748 ± 115 | NA |
| DC101 | 400 μg 3×/wk | 11.6 ± 0.4 | 896 ± 95 | ≤ .001 |
| 6.12 | 800 μg 2×/wk | 12.0 ± 0.5 | 941 ± 115 | ≤ .001 |
| 6.12 + DC | 800 μg 2×/wk and 400 μg 3×/wk | 9.9 ± 0.6 | 558 ± 103 | ≤ .0001 |
Mean tumor volume on treatment day 21 is shown (n = 5-10 animals per group). NA indicates not applicable.